Evidence map›Paper›PMID 34242269›Full record

ArticlePloS one2021

The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.

Karys M Hildebrand, Arvind K Singla, Reid McNeil, Kayla L Marritt, Kurt N Hildebrand, Franz Zemp, Jahanara Rajwani, Doha Itani, Pinaki Bose, Douglas J Mahoney and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. VSVNature communications · 2024
    Article
  8. Review
  9. Article
  10. Emerging mechanisms of immunotherapy resistance in sarcomas.Cancer drug resistance (Alhambra, Calif.) · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Karys M HildebrandDepartment of Surgery, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Arvind K SinglaDepartment of Surgery, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Reid McNeilArnie Charbonneau Cancer Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Kayla L MarrittDepartment of Surgery, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Kurt N HildebrandDepartment of Surgery, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Franz ZempArnie Charbonneau Cancer Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Jahanara RajwaniArnie Charbonneau Cancer Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0003-3409-4319
Doha ItaniDepartment of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI, United States of America.
Pinaki BoseArnie Charbonneau Cancer Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Douglas J MahoneyArnie Charbonneau Cancer Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Frank R JirikMcCaig Bone and Joint Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Michael J MonumentDepartment of Surgery, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
University of Calgary · CAMedical College of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcomas are rare, difficult to treat, mesenchymal lineage tumours that affect children and adults. Immunologically-based therapies have improved outcomes for numerous adult cancers, however, these therapeutic strategies have been minimally effective in sarcoma so far. Clinically relevant, immunologically-competent, and transplantable pre-clinical sarcoma models are essential to advance sarcoma immunology research. Herein we show that Cre-mediated activation of KrasG12D, and deletion of Trp53, in the hindlimb muscles of C57Bl/6 mice results in the highly penetrant, rapid onset undifferentiated pleomorphic sarcomas (UPS), one of the most common human sarcoma subtypes. Cell lines derived from spontaneous UPS tumours can be reproducibly transplanted into the hindlimbs or lungs of naïve, immune competent syngeneic mice. Immunological characterization of both spontaneous and transplanted UPS tumours demonstrates an immunologically-'quiescent' microenvironment, characterized by a paucity of lymphocytes, limited spontaneous adaptive immune pathways, and dense macrophage infiltrates. Macrophages are the dominant immune population in both spontaneous and transplanted UPS tumours, although compared to spontaneous tumours, transplanted tumours demonstrate increased spontaneous lymphocytic infiltrates. The growth of transplanted UPS tumours is unaffected by host lymphocyte deficiency, and despite strong expression of PD-1 on tumour infiltrating lymphocytes, tumours are resistant to immunological checkpoint blockade. This spontaneous and transplantable immune competent UPS model will be an important experimental tool in the pre-clinical development and evaluation of novel immunotherapeutic approaches for immunologically cold soft tissue sarcomas.

Indexed as

AnimalsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmFemaleHindlimbHumansImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingMacrophagesMaleMiceMice, TransgenicMuscle NeoplasmsMuscle, SkeletalMutationHras protein, mouseImmune Checkpoint InhibitorsProto-Oncogene Proteins p21(ras)Trp53 protein, mouseTumor Suppressor Protein p53

Identifiers

PMID34242269
PMCPMC8270133
OpenAlexW3182840620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.